{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:26:48Z","timestamp":1793608008415,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00051"],"award-info":[{"award-number":["75N93019C00051"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032160","name":"Task Force for Global Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032160","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["214596\/Z\/18\/Z"],"award-info":[{"award-number":["214596\/Z\/18\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["225160\/Z\/22\/Z"],"award-info":[{"award-number":["225160\/Z\/22\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.vaccine.2026.129135","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:46:11Z","timestamp":1789699571000},"page":"129135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Innovation, development, and licensure of improved influenza vaccines: the way forward"],"prefix":"10.1016","volume":"92","author":[{"given":"Julia T.","family":"Ostrowsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce G.","family":"Gellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cavaleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Bresee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Venkayya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Jane","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Schultz-Cherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"Hollingsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanta","family":"Subbarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan C.","family":"Settembre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Belongia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"McCauley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Rappuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Cowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Taaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie C.","family":"Vestin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela J.","family":"Mehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela K.","family":"Ulrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Osterholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine A.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.129135_bb0005","series-title":"2009 H1N1 flu pandemic timeline","author":"CDC","year":"2019"},{"key":"10.1016\/j.vaccine.2026.129135_bb0010","series-title":"Update: novel influenza A (H1N1) virus infections \u2014 worldwide","author":"CDC","year":"2009"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129135_bb0015","article-title":"Pandemic influenza vaccine: characterization of A\/California\/07\/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability","author":"Feshchenko","year":"2012","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.vaccine.2026.129135_bb0020","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1503\/cmaj.100900","article-title":"Pandemic (H1N1) 2009: assessing the response","volume":"182","author":"Low","year":"2010","journal-title":"CMAJ Can Med Assoc J"},{"key":"10.1016\/j.vaccine.2026.129135_bb0025","series-title":"The 2009 H1N1 influenza vaccination campaign: summary of a workshop series","author":"Institute of Medicine","year":"2010"},{"key":"10.1016\/j.vaccine.2026.129135_bb0030","series-title":"The compelling need for game-changing influenza vaccines","author":"Osterholm","year":"2012"},{"key":"10.1016\/j.vaccine.2026.129135_bb0035","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1093\/infdis\/jis535","article-title":"2009 pandemic influenza a virus subtype H1N1 vaccination in Africa\u2014successes and challenges","volume":"206","author":"Mihigo","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129135_bb0040","author":"WHO Global Influenza Programme"},{"key":"10.1016\/j.vaccine.2026.129135_bb0045","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s41586-024-08054-z","article-title":"The global H5N1 influenza panzootic in mammals","volume":"637","author":"Peacock","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.129135_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126839","article-title":"Global production capacity of seasonal and pandemic influenza vaccines in 2023","volume":"51","author":"Taaffe","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129135_bb0055","series-title":"Vaccines pandemic influenza","first-page":"43","article-title":"Seasonal influenza vaccines","author":"Fiore","year":"2009"},{"key":"10.1016\/j.vaccine.2026.129135_bb0060","article-title":"An overview of influenza H5 vaccines","volume":"0","author":"Taaffe","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2026.129135_bb0065","unstructured":"WHO. Considerations for use of avian influenza A(H5) vaccines during the interpandemic and emergence periods: report of a WHO virtual scientific consultation, September 2024. https:\/\/www.who.int\/publications\/i\/item\/978924011146223. 23 June 2025."},{"key":"10.1016\/j.vaccine.2026.129135_bb0070","doi-asserted-by":"crossref","first-page":"S405","DOI":"10.1093\/infdis\/jiab269","article-title":"Influenza vaccines: successes and continuing challenges","volume":"224","author":"Becker","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129135_bb0080","unstructured":"WHO Seasonal Influenza Vaccine Global Market Study January 2024. https:\/\/www.who.int\/publications\/m\/item\/who-seasonal-influenza-vaccine-global-market-study-january- 2024; 31 January 2024. [Accessed 15 July 2026]."},{"key":"10.1016\/j.vaccine.2026.129135_bb0085","series-title":"Pandemic influenza preparedness framework for the sharing of influenza viruses and access to vaccines and other benefits","author":"WHO","year":"2022"},{"key":"10.1016\/j.vaccine.2026.129135_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines13121206","article-title":"Research priorities for zoonotic and pandemic influenza vaccines: evidence and recommendations from the WHO public health research agenda for influenza (2024 update)","volume":"13","author":"Zhang","year":"2025","journal-title":"Vaccines"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2026.129135_bb0095","article-title":"Evaluating the broader impact of improved influenza vaccines: a full value of vaccine assessment approach","volume":"60","author":"Soble","year":"2026","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129135_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2026.128391","article-title":"Influenza vaccine recommendations and coverage (2018\u20132023): a foundation for pandemic preparedness and response","volume":"78","author":"Mesl\u00e9","year":"2026","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129135_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2026.128273","article-title":"Pathways to economically viable and sustainable vaccine manufacturing in LMICs","author":"Helble","year":"2026","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129135_bb0110","series-title":"WHO preferred product characteristics for next generation influenza vaccines","author":"WHO","year":"2025"},{"key":"10.1016\/j.vaccine.2026.129135_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines14030247","article-title":"mRNA and next-generation vaccine platforms for pandemic influenza preparedness","volume":"14","author":"Bright","year":"2026","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.129135_bb0120","series-title":"Influenza (seasonal)","author":"WHO","year":"2025"},{"key":"10.1016\/j.vaccine.2026.129135_bb0125","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.129135_bb0130","author":"CDC"},{"key":"10.1016\/j.vaccine.2026.129135_bb0135","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cmi.2025.09.023","article-title":"Effectiveness of influenza vaccination to prevent severe disease: a systematic review and meta-analysis of test-negative design studies","volume":"32","author":"Yegorov","year":"2026","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2026.129135_bb0140","author":"CDC"},{"key":"10.1016\/j.vaccine.2026.129135_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127747","article-title":"The IFPMA IVS seasonal influenza vaccine dose distribution survey 2022\u20132023: evidence of the need for committed national investment in and uptake of seasonal influenza vaccination","volume":"64","author":"Palache","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129135_bb0150","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.14620","article-title":"High-dose vs standard-dose influenza vaccines in older adults: a meta-analysis","volume":"9","author":"Skaarup","year":"2026","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2026.129135_bb0155","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1016\/j.vaccine.2022.04.019","article-title":"Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective \u2013 a systematic review of recently published literature on real-world data","volume":"40","author":"G\u00e4rtner","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129135_bb0160","article-title":"Recent advances in the influenza virus vaccine landscape: a comprehensive overview of technologies and trials","volume":"0","author":"Clark","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2026.129135_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.70020","article-title":"Relative efficacy, effectiveness and safety of newer and\/or enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over: update of a systematic review","volume":"35","author":"Askar","year":"2025","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2026.129135_bb0170","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3390\/vaccines11101607","article-title":"Effectiveness of cell-based quadrivalent seasonal influenza vaccine: a systematic review and Meta-analysis","volume":"11","author":"Coleman","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.129135_bb0175","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/infdis\/jiy103","article-title":"A universal influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases","volume":"218","author":"Erbelding","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129135_bb0180","series-title":"Accelerating the development of a universal influenza vaccine","author":"Sabin-Aspen Vaccine Science Policy Group","year":"2019"},{"key":"10.1016\/j.vaccine.2026.129135_bb0185","author":"Gates Foundation"},{"key":"10.1016\/j.vaccine.2026.129135_bb0190","article-title":"Novel universal vaccines to mitigate emerging avian influenza viruses","author":"Liu","year":"2025","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.vaccine.2026.129135_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126408","article-title":"Advancing influenza vaccines: a review of next-generation candidates and their potential for global health impact","volume":"42","author":"Taaffe","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129135_bb0200","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.3390\/vaccines13111164","article-title":"Brief comparison of novel influenza vaccine design strategies","volume":"13","author":"Chai","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.129135_bb0205","series-title":"On behalf of the Center for Infectious Disease Research and Policy (CIDRAP) Influenza Vaccines R&D Roadmap (IVR) Initiative team","author":"Ostrowsky","year":"2025"},{"key":"10.1016\/j.vaccine.2026.129135_bb0210","series-title":"Moderna receives European Commission marketing authorization for mCOMBRIAX, Moderna\u2019s mRNA combination vaccine against influenza and COVID-19","author":"ModernaTX, Inc.","year":"2026"},{"key":"10.1016\/j.vaccine.2026.129135_bb0215","author":"European Medicines Agency"},{"key":"10.1016\/j.vaccine.2026.129135_bb0220","unstructured":"ModernaTX Inc. Moderna receives U.S FDA approval for influenza vaccine mFLUSIVA. August;5:2026.https:\/\/www.accessnewswire.com\/newsroom\/en\/healthcare-and-pharmaceutical\/moderna-receives-u.s.-fda-approval-for-influenza-vaccine-mflusiva-1201472."},{"key":"10.1016\/j.vaccine.2026.129135_bb0225","author":"Novavax"},{"key":"10.1016\/j.vaccine.2026.129135_bb0230","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.vaccine.2018.11.037","article-title":"Global funders consortium for universal influenza vaccine development","volume":"37","author":"Bresee","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129135_bb0235","author":"CIDRAP"},{"key":"10.1016\/j.vaccine.2026.129135_bb0240","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.1016\/j.vaccine.2021.08.010","article-title":"A Research and Development (R&D) roadmap for influenza vaccines: looking toward the future","volume":"39","author":"Moore","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129135_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127431","article-title":"Accomplishments and challenges in developing improved influenza vaccines: an evaluation of three years of progress toward the milestones of the influenza vaccines research and development roadmap","volume":"61","author":"Ostrowsky","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129135_bb0250","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.coviro.2020.02.003","article-title":"Tracking progress in universal influenza vaccine development","volume":"40","author":"Ostrowsky","year":"2020","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2026.129135_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127967","article-title":"Funding the priorities of the influenza vaccines research and development roadmap: an evaluation of global investment","volume":"69","author":"Ulrich","year":"2026","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129135_bb0260","doi-asserted-by":"crossref","DOI":"10.1111\/irv.70258","article-title":"Meeting report: fourth correlates of protection for next generation influenza vaccines","volume":"20","author":"Tscherne","year":"2026","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2026.129135_bb0265","article-title":"Exclusive: key US infectious-diseases centre to drop pandemic preparation","author":"Kozlov","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.129135_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)00136-8","article-title":"Confronting the evolution and expansion of anti-vaccine activism in the USA in the COVID-19 era","author":"Carpiano","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.129135_bb0275","first-page":"1","article-title":"The new vision from the National Institute of Allergy and Infectious Diseases (NIAID)","author":"Taubenberger","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.129135_bb0280","doi-asserted-by":"crossref","DOI":"10.1089\/hs.2024.0074","article-title":"Building a fast response capability for emerging infectious diseases within the biomedical advanced research and development authority","author":"Johnson","year":"2025","journal-title":"Health Secur"},{"key":"10.1016\/j.vaccine.2026.129135_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127118","article-title":"Collaborative influenza vaccine innovation centers (CIVICs) program","volume":"54","author":"Singleton","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129135_bb0290","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.vaccine.2023.07.041","article-title":"Benefit-risk assessment of vaccines","volume":"42","author":"Kochhar","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129135_bb0295","first-page":"1","article-title":"mRNA vaccines for infectious diseases \u2014 advances, challenges and opportunities","author":"Pardi","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2026.129135_bb0300","doi-asserted-by":"crossref","DOI":"10.1111\/1751-7915.70212","article-title":"Harnessing the potential of mRNA vaccines against infectious diseases","volume":"18","author":"Rezk","year":"2025","journal-title":"Microb Biotechnol"},{"key":"10.1016\/j.vaccine.2026.129135_bb0305","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2026.2694211","article-title":"Optimized seasonal influenza mRNA vaccine compositions demonstrate safety and enhanced immunogenicity in a phase 2 study","volume":"22","author":"Fierro","year":"2026","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.129135_bb0310","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa2516491","article-title":"Efficacy and safety of an mRNA seasonal influenza vaccine in adults","volume":"394","author":"Leroux-Roels","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.129135_bb0315","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2416779","article-title":"Efficacy, immunogenicity, and safety of modified mRNA influenza vaccine","volume":"393","author":"Fitz-Patrick","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.129135_bb0320","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adu3791","article-title":"Vaccinology in the artificial intelligence era","volume":"17","author":"Gasperini","year":"2025","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2026.129135_bb0325","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1126\/science.adw3278","article-title":"Prepare now for a potential H5N1 pandemic","volume":"387","author":"Goodman","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.129135_bb0330","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2025.1613869","article-title":"Highly pathogenic avian influenza: pandemic preparedness for a scenario of high lethality with no vaccines","volume":"13","author":"Possas","year":"2025","journal-title":"Front Public Health"},{"key":"10.1016\/j.vaccine.2026.129135_bb0335","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41541-025-01211-z","article-title":"De-risking vaccine development: lessons, challenges, and prospects","volume":"10","author":"Masignani","year":"2025","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.vaccine.2026.129135_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-024-00873-5","article-title":"The role of correlates of protection in overcoming barriers to vaccine development and demonstrating efficacy","volume":"9","author":"King","year":"2024","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.vaccine.2026.129135_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1568778","article-title":"Development of an intranasal, universal influenza vaccine in an EU funded public-private partnership: the FLUniversal consortium","volume":"16","author":"Cnossen","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.129135_bb0350","article-title":"Protecting the future of vaccine development amidst US funding withdrawal for mRNA vaccine research","volume":"0","author":"Petersen","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2026.129135_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(25)00068-4","article-title":"Europe needs a sustainably funded influenza research and response network","author":"Krammer","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129135_bb0360","article-title":"Strategic and scientific contributions of human challenge trials for vaccine development: facts versus fantasy","volume":"0","author":"Abo","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129135_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.biologicals.2025.101818","article-title":"Regulatory workshop on standardisation of clinical procedures, endpoints and data robustness of human challenge studies \u2013 a stakeholder meeting report","volume":"90","author":"Meln","year":"2025","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2026.129135_bb0370","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adx1794","article-title":"Assessing AI\u2019s cognitive abilities for scientific discovery in the field of systems vaccinology","volume":"10","author":"Rodriguez-Coffinet","year":"2025","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2026.129135_bb0375","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1016\/j.cell.2024.07.021","article-title":"Transforming vaccinology","volume":"187","author":"Rappuoli","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2026.129135_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1584738","article-title":"T cells responses after vaccination: a regulatory perspective","volume":"16","author":"Buoninfante","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.129135_bb0385","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaf290","article-title":"First among equals: the case for high-quality clinical data in influenza vaccines","author":"Manning","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129135_bb0390","series-title":"Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines","author":"FDA","year":"2007"},{"key":"10.1016\/j.vaccine.2026.129135_bb0395","series-title":"Key considerations for the development of novel mRNA candidate vaccines in LMICs: a WHO\/MPP mRNA Technology Transfer Programme meeting report - ClinicalKey","author":"Gsell","year":"2023"},{"key":"10.1016\/j.vaccine.2026.129135_bb0400","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines14060519","article-title":"From global insights to local action: bridging vaccine design and manufacturing gaps in H5N1 pandemic readiness","volume":"14","author":"Delfino","year":"2026","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.129135_bb0410","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines14040324","article-title":"Unpacking the mRNA supply chain: challenges and opportunities for global health","volume":"14","author":"Lopes de Abreu","year":"2026","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.129135_bb0415","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3390\/v15010199","article-title":"Which virus will cause the next pandemic?","volume":"15","author":"Neumann","year":"2023","journal-title":"Viruses"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:35:56Z","timestamp":1793604956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26009448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":81,"alternative-id":["S0264410X26009448"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129135","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovation, development, and licensure of improved influenza vaccines: the way forward","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129135","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129135"}}